Glp-1 helps control blood sugar in type 2 diabetes by increasing insulin when needed, reducing glucose production in the liver, slowing digestion, and decreasing appetite
Increasing prevalence of type 2 diabetes and healthcare reimbursement and access are some of the major factors which attributed to the boost the growth of the market over the forecast period
Weight loss was discovered as a beneficial side effect during clinical trials, leading Novo Nordisk to develop Wegovy as a dedicated obesity treatment using the same molecule at higher doses
Association of largest meal timing and eating frequency with body mass index and obesity
Pancreatic proglucagon gene expression is promoted upon fasting and hypoglycaemia induction and inhibited by insulin
This is especially useful for clinics, weight loss programs, and patients who need customized care